TBPH — Theravance Biopharma Inc
NASDAQ · Healthcare · Biotechnology
$17.05
+$0.02 (+0.15%)
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ. It is led by Rick E. Winningham M.B.A., based in 901 Gateway Boulevard, South San Francisco, CA, United States, 94080, with about 90 employees. Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Latest reported TBPH revenue for 2025-09-30 was $20.0M. Net income was $44.9M. Revenue was down 23.7% from 2025-06-30 to 2025-09-30. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Use this TBPH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TBPH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TBPH SEC filings page. Lician reads the product cache first so this HTML stays unique to Theravance Biopharma Inc even when a live quote feed is slow.
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
TBPH Key Statistics
Market Cap
$861.45M
Volume
331,779
Previous Close
$17.01
Day Range
$17.00 – $17.07
P/E Ratio
7.49
P/B Ratio
2.96
EPS
-$0.31
Revenue
$18.75M
Net Income
-$15.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+6.8%
Profit Margin
-82.8%
Employees
90
TBPH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $18.75M | $17.57M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$15.53M | -$8.51M |
| EPS (Diluted) | -$0.31 | -$0.17 |
Total Assets
$354.16M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$37.80M
Operating Cash Flow
-$11.54M
Free Cash Flow
$0.00
Theravance Biopharma Inc Company Information
- CEO & Director
- Rick E. Winningham M.B.A.
- Headquarters
- 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Website
- www.theravance.com
- Phone
- 650 808 6000
- IPO / Founded
- 2014-05-16
- Sector
- Healthcare
- Industry
- Biotechnology